Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: A retrospective cohort from the European Task Force of Dermatology for Cancer patients

Affiliations

• ¹ Department of Dermatology, Hospital Clínic de Barcelona, FRCB, Universitat de Barcelona, Barcelona, Spain.
• ² DermatoOncology Department, Andreas Sygros Hospital, University of Athens, Athens, Greece.
• ³ Dermatology and Oncology Department, Istituto Oncologico Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
• ⁴ Second Department of Dermatology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
• ⁵ Servicio de Dermatología, Hospital Universitario La Paz, Madrid, Spain.
• ⁶ Dermatology Department, General University Hospital of Patra, Patra, Greece.
• ⁷ Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
• ⁸ Departments of Oncodermatology and Clinical Research, Oncopole Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
• ⁹ Department of Dermatology, Hospital Clínic de Barcelona, FRCB, Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. Electronic address: ccarrera@clinic.cat.